184 related articles for article (PubMed ID: 2463099)
1. The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies.
Li JL; Shen GL; Ghetie MA; May RD; Till M; Ghetie V; Uhr JW; Janossy G; Thorpe PE; Amlot P
Cell Immunol; 1989 Jan; 118(1):85-99. PubMed ID: 2463099
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
Shen GL; Li JL; Ghetie MA; Ghetie V; May RD; Till M; Brown AN; Relf M; Knowles P; Uhr JW
Int J Cancer; 1988 Nov; 42(5):792-7. PubMed ID: 3263328
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
4. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
Mansfield E; Amlot P; Pastan I; FitzGerald DJ
Blood; 1997 Sep; 90(5):2020-6. PubMed ID: 9292538
[TBL] [Abstract][Full Text] [Related]
5. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys.
Kreitman RJ; Wang QC; FitzGerald DJ; Pastan I
Int J Cancer; 1999 Mar; 81(1):148-55. PubMed ID: 10077166
[TBL] [Abstract][Full Text] [Related]
6. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
Blood; 1992 Nov; 80(9):2315-20. PubMed ID: 1384801
[TBL] [Abstract][Full Text] [Related]
7. Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand.
Engel P; Wagner N; Miller AS; Tedder TF
J Exp Med; 1995 Apr; 181(4):1581-6. PubMed ID: 7535343
[TBL] [Abstract][Full Text] [Related]
8. CD22 antigen: biosynthesis, glycosylation and surface expression of a B lymphocyte protein involved in B cell activation and adhesion.
Schwartz-Albiez R; Dörken B; Monner DA; Moldenhauer G
Int Immunol; 1991 Jul; 3(7):623-33. PubMed ID: 1716973
[TBL] [Abstract][Full Text] [Related]
9. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
[TBL] [Abstract][Full Text] [Related]
10. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins.
Herrera L; Yarbrough S; Ghetie V; Aquino DB; Vitetta ES
Leukemia; 2003 Feb; 17(2):334-8. PubMed ID: 12592332
[TBL] [Abstract][Full Text] [Related]
11. The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes.
Engel P; Nojima Y; Rothstein D; Zhou LJ; Wilson GL; Kehrl JH; Tedder TF
J Immunol; 1993 Jun; 150(11):4719-32. PubMed ID: 7684411
[TBL] [Abstract][Full Text] [Related]
12. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro.
Herrera L; Farah RA; Pellegrini VA; Aquino DB; Sandler ES; Buchanan GR; Vitetta ES
Leukemia; 2000 May; 14(5):853-8. PubMed ID: 10803517
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
14. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
French RR; Penney CA; Browning AC; Stirpe F; George AJ; Glennie MJ
Br J Cancer; 1995 May; 71(5):986-94. PubMed ID: 7734325
[TBL] [Abstract][Full Text] [Related]
15. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
DiJoseph JF; Popplewell A; Tickle S; Ladyman H; Lawson A; Kunz A; Khandke K; Armellino DC; Boghaert ER; Hamann P; Zinkewich-Peotti K; Stephens S; Weir N; Damle NK
Cancer Immunol Immunother; 2005 Jan; 54(1):11-24. PubMed ID: 15693135
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
Tuscano JM; O'Donnell RT; Miers LA; Kroger LA; Kukis DL; Lamborn KR; Tedder TF; DeNardo GL
Blood; 2003 May; 101(9):3641-7. PubMed ID: 12511412
[TBL] [Abstract][Full Text] [Related]
17. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
18. Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2.
Stein R; Belisle E; Hansen HJ; Goldenberg DM
Cancer Immunol Immunother; 1993 Oct; 37(5):293-8. PubMed ID: 7691407
[TBL] [Abstract][Full Text] [Related]
19. Difference in CD22 molecules in human B cells and basophils.
Toba K; Hanawa H; Fuse I; Sakaue M; Watanabe K; Uesugi Y; Higuchi W; Takahashi M; Aizawa Y
Exp Hematol; 2002 Mar; 30(3):205-11. PubMed ID: 11882357
[TBL] [Abstract][Full Text] [Related]
20. B-cell restricted saporin immunotoxins: activity against B-cell lines and chronic lymphocytic leukemia cells.
Bregni M; Siena S; Formosa A; Lappi DA; Martineau D; Malavasi F; Dorken B; Bonadonna G; Gianni AM
Blood; 1989 Feb; 73(3):753-62. PubMed ID: 2465042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]